Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer

Overview

This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer.

Full Title of Study: “A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2012

Detailed Description

This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer. This research treatment will evaluate the combination of two chemotherapy agents, oxaliplatin and gemcitabine with radiation therapy. The researchers have already done studies using oxaliplatin, gemcitabine and radiation therapy together for pancreatic cancer. They want to build on the information they have from this previous research and do the research at multiple sites. They will use this study to determine how well people do who are treated with gemcitabine, oxaliplatin, and radiation therapy prior to having surgery for their pancreatic cancer. The researchers will also gather more information about what type of side effects occur with this treatment.

Interventions

  • Drug: gemcitabine
    • Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.
  • Drug: oxaliplatin
    • Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.
  • Procedure: Radiation
    • The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.

Arms, Groups and Cohorts

  • Experimental: Oxaliplatin & gemcitabine with radiation
    • This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer.

Clinical Trial Outcome Measures

Primary Measures

  • Two-year Disease Free Survival.
    • Time Frame: two years
    • The percent of patients alive and disease-free at two years.

Secondary Measures

  • Time to Treatment Failure
    • Time Frame: 2 years
    • Median time for disease recurrence after surgery.
  • Overall Survival
    • Time Frame: 5 years
    • Percent overall survival was calculated for all evaluable patients.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients must have cytologic or histologic confirmation of carcinoma arising in the pancreas. – Patients must be deemed resectable or borderline resectable based on criteria in section 4.2 prior to registration. – Patients must have an expected life expectancy of at least 12 weeks and a Zubrod performance status of < 2. – Patients must have adequate organ function defined as follows: absolute neutrophil count of > 1500/mm3, platelets > 100,000/mm3, serum Cr < 1.5 mg/dl, total bilirubin < 3.0 mg/dl with relief of biliary obstruction if present (PTC tube or endobiliary stent). – Patients must be free of other active systemic malignancy, ongoing infection, including HIV infection, or any other serious uncontrolled, concomitant systemic disorders or psychiatric condition that would interfere with the safe delivery of protocol therapy. – Patients must be aware of the investigational nature of the therapy and provide written informed consent. – Patients must have no history of previous chemotherapy for pancreatic cancer or any abdominal radiation therapy. – Patients must not have used any investigational agent in the month before enrollment into the study. Exclusion Criteria:

  • Patients with neuroendocrine tumors are excluded. – Patients with preexisting peripheral neuropathy > grade 2 are ineligible. – Pregnant or nursing women are ineligible and patients of reproductive potential must agree to use an effective contraceptive method during participation in this trial and for 6 months after trial.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Michigan Rogel Cancer Center
  • Collaborator
    • Sanofi
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Mark Zalupski, MD, Principal Investigator, University of Michigan

Citations Reporting on Results

Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LA, Griffith KA, Francis IR, Greenson JK, Simeone DM, Lawrence TS, Laheru D, Wolfgang CL, Williams T, Bloomston M, Moore MJ, Wei A, Zalupski MM. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer. 2013 Aug 1;119(15):2692-700. doi: 10.1002/cncr.28117. Epub 2013 May 29.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.